Effects of tafamidis on exercise capacity, cardiac function and myocardial amyloid deposition in patients with transthyretin amyloid cardiomyopathy

被引：0
|
作者：
Rettl, R. [1 ]
Mann, C. [1 ]
Dachs, T. [1 ]
Duca, F. [1 ]
Binder, C. [1 ]
Dusik, F. [1 ]
Seirer, B. [1 ]
Eslam, R. Badr [1 ]
Hengstenberg, C. [1 ]
Bonderman, D. [1 ]
机构：
[1] Med Univ Vienna, Vienna, Austria
来源：
EUROPEAN HEART JOURNAL | 2020年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1029 / 1029
页数：1
相关论文
共 50 条
  • [21] Tafamidis for Transthyretin Amyloid Cardiomyopathy Reply
    Maurer, Mathew S.
    Sultan, Marla B.
    Rapezzi, Claudio
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (02) : 196 - 197
  • [22] A Systematic Review of Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
    Singh, Bishnu Mohan
    Bohara, Narayan
    Gautam, Kamal
    Basnet, Madan
    Sistu, K. C.
    Binod, K. C.
    Raut, Anuradha
    Phudong, Abisha
    Gautam, Jeevan
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (09)
  • [23] Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy
    Yvette N. Lamb
    American Journal of Cardiovascular Drugs, 2021, 21 : 113 - 121
  • [24] Benefits of tafamidis in patients with advanced transthyretin amyloid cardiomyopathy
    Rapezzi, C.
    Kristen, A., V
    Gundapaneni, B.
    Sultan, M. B.
    Hanna, M.
    EUROPEAN HEART JOURNAL, 2020, 41 : 2115 - 2115
  • [25] Tafamidis in Transthyretin Amyloid Cardiomyopathy Effects on Transthyretin Stabilization and Clinical Outcomes
    Maurer, Mathew S.
    Grogan, Donna R.
    Judge, Daniel P.
    Mundayat, Rajiv
    Packman, Jeff
    Lombardo, Ilise
    Quyyumi, Arshed A.
    Aarts, Janske
    Falk, Rodney H.
    CIRCULATION-HEART FAILURE, 2015, 8 (03) : 519 - 526
  • [26] Cardiac disease monitoring measures in patients with transthyretin amyloid cardiomyopathy treated with tafamidis
    Bampatsias, Dimitrios
    Wardhere, Abdirahman
    Zeldin, Lawrence
    Mirabal-Santos, Alfonsina
    Weinsaft, Ariel Y.
    Levy, Juliana C.
    Smiley, Dia
    Teruya, Sergio L.
    Maurer, Mathew S.
    HEART, 2025,
  • [27] Tafamidis (Vyndaqel; Vyndamax) for Transthyretin Amyloid Cardiomyopathy
    Abramowicz, Mark
    Zuccotti, Gianna
    Pflomm, Jean-Marie
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (05): : 505 - 505
  • [28] Tafamidis A Novel Treatment for Transthyretin Amyloid Cardiomyopathy
    Nawarskas, James J.
    Shephard, Emily A.
    CARDIOLOGY IN REVIEW, 2020, 28 (03) : 156 - 160
  • [29] Outcomes of Octogenarian Patients Treated with Tafamidis for Transthyretin Amyloid Cardiomyopathy
    Sarkar, Abdullah
    Sanchez-Nadales, Alejandro
    Kunutsor, Setor K.
    Hanna, Mazen A.
    Asher, Craig R.
    Wolinsky, David G.
    AMERICAN JOURNAL OF CARDIOLOGY, 2024, 214 : 144 - 148
  • [30] Safety and efficacy of tafamidis in Chinese patients with transthyretin amyloid cardiomyopathy
    Tian, Zhuang
    Peng, Daoquan
    Ma, Wei
    Yan, Jiangtao
    Wang, Jian'an
    Jin, Wei
    Tang, Yida
    Liu, Ying
    Jia, Caiping
    Gao, Yingxu
    Sun, Qiankun
    Angeli, Franca S.
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2024, 31 : S2 - S3
12345